All In Biotech

Drug Trial Radar · NCT07804186

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

A Randomized, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Sep 4, 2026

Primary completion

Mar 2034

Study completion Apr 2034

Sponsor

Lead sponsor
IDEAYA BiosciencesIndustry
Sponsor type
Industry
First posted
Sep 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)

Conditions

  • Uveal Melanoma

Interventions

  • DarovasertibDrug

    Oral, selectively targets key proteins

  • Crizotinib (Xalkori)Drug

    Oral small molecule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median relapse-free survivalTime frame: Approximately 5 years

Locations

29 sites in 6 countries. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona · Recruiting

  • UCLA Medical Center

    Los Angeles, California · Not yet recruiting

  • Angeles Clinic

    Los Angeles, California · Not yet recruiting

  • University of California, San Diego

    San Diego, California · Not yet recruiting

  • Sutter Health CPMC

    San Francisco, California · Not yet recruiting

  • University of California, San Francisco

    San Francisco, California · Not yet recruiting

  • University of Miami

    Miami, Florida · Not yet recruiting

  • USF Health Eye Institute

    Tampa, Florida · Not yet recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Not yet recruiting

  • Cancer Hematology Centers Western Michigan

    Grand Rapids, Michigan · Not yet recruiting

  • Columbia University - Herbert Irving Comprehensive Cancer Center

    New York, New York · Not yet recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Not yet recruiting

  • Northwell Health

    New York, New York · Not yet recruiting

  • Duke Cancer Center

    Raleigh, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Wills Eye Hospital at Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute (SCRI)

    Nashville, Tennessee · Recruiting

  • The University of Texas Southwestern Medical Center

    Dallas, Texas · Not yet recruiting

  • UT MD Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • University of Wisconsin Health

    Madison, Wisconsin · Not yet recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Not yet recruiting

  • Alfred Health

    Melbourne, Victoria, Australia · Not yet recruiting

  • Universite de Montreal - Centre de Recherche du Centre Hospitalier de l'Universite de Montreal

    Montréal, Ontario, Canada · Not yet recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Hadassah Medical Center

    Jerusalem, Israel · Not yet recruiting

  • Sheba Medical Center

    Ramat Gan, Israel · Not yet recruiting

  • University of Zurich Hospital

    Zurich, Switzerland · Not yet recruiting

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom · Not yet recruiting

  • Mount Vernon Hospital

    Northwood, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.